AAV2-mediated gene delivery to monkey putamen: Evaluation of an infusion device and delivery parameters
Introduction
PD is characterized in part by the progressive loss of dopaminergic neurons in the substantia nigra and a severe decrease of dopamine in the putamen (Hornykiewicz, 1975). Aromatic l-amino acid decarboxylase (AADC) is an enzyme in the dopamine biosynthetic pathway that converts l-dopa to dopamine. We have previously shown that transfer of the cDNA encoding human AADC to rat or non-human primate putamen can reduce effective l-dopa doses in animal models of PD, and thereby restore dopamine to normal levels (Bankiewicz et al., 2000, Sanchez-Pernaute et al., 2001). In human PD patients, this therapy would be expected to lower l-dopa requirements and extend the duration during which clinical benefit of the drug is observed. A challenging feature of this therapy is that vector infusion must be quantitatively and accurately delivered to the putamen and distribution should be as diffuse from the needle delivery site as possible. Focal, concentrated delivery and expression of AADC could result in localized dopamine production in the putamen that may be undesirable.
Parkinsonian rhesus macaques have been used in pharmacological studies with the AADC gene expressed from a recombinant AAV2 vector with a CMV enhancer and promoter (AAV-hAADC-2) (Bankiewicz et al., 2000). The vector was infused by CED with a ramped infusion procedure through a prototype delivery device (“preclinical”) composed of a short fused silica catheter connected to a syringe pump by Teflon tubing. Although a standardized preclinical device was proven safe for delivery of vector to the putamen of non-human primates (Bankiewicz et al., 2000), an unacceptable amount of the vector was lost by adsorption to Teflon. The relatively large hold-up volume (or internal volume) of the Teflon tubing also required that the syringe and proximal end of the tubing (end furthest from the cannula) be filled with oil to conserve vector. Thus, a new device (Clinical Device B) was designed for administration of AAV2 vector to humans.
The clinical infusion device was designed to (1) minimize vector loss to the internal surfaces of the catheter and tubing, (2) minimize the hold-up volume of the device such that vector could be dispensed from a syringe placed approximately 1.2 m away from the site of infusion, (3) strengthen and lengthen the cannula material for added stability in the larger human brain, (4) attach to a commonly used stereotaxic surgery frame, and (5) allow manufacturing of a device in compliance with quality system requirements (QSR) for medical devices. The end product of these design requirements was Clinical Device B, a stereotaxic frame-compatible surgical steel cannula and Teflon tubing that are lined with fused silica and fitted to a standard Luer lock at the proximal end for attachment to a programmable syringe pump.
Macromolecules can be administered to large areas of the brain by taking advantage of fluid convection through interstitial spaces in the brain (Bobo et al., 1994, Lieberman et al., 1995). Maximal volume of distribution is achieved by applying a pressure gradient and optimizing dose, infusion time, and volume (Kroll et al., 1996). Typically, the infusion rate is ramped up over about 30 min to avoid an initial pressure buildup at the infusion site that could result in reflux of product along the needle track. However, a non-ramped delivery procedure would allow for a simpler infusion protocol and shorter infusion times that are important considerations for clinical success. The goal of this study was to evaluate the safety and efficacy of the new infusion device (Clinical Device B) and to compare ramped vs. non-ramped infusion procedures in normal monkeys. The primary endpoints of the present study were vector distribution as measured by immunohistochemistry for hAADC expression, and safety as evaluated by clinical observations, histopathology, and antibody formation.
Section snippets
Recombinant vector production
Recombinant AAV2 was generated by a triple transfection protocol (Matsushita et al., 1998). Briefly, after expansion of cells from the HEK 293 working cell bank through a series of disposable culture ware in DMEM containing 10% fetal bovine serum and 2 mM glutamine, cells were co-transfected with 3 plasmids (pAAV-hAADC-2, pHLP19 and pladeno5). After an appropriate transfection time, the medium containing the transfection reagent was replaced with serum-free medium and the cells were incubated
Experimental design
Recombinant AAV2 vectors transduce brain tissue efficiently, but transduction levels decline significantly in the presence of high neutralizing antibody (NAb) titers (>1:1200) (Sanftner et al., 2004). Therefore, 4 male rhesus monkeys with NAb titers of ≤1:100 were selected for AAV2 infusions (Table 1). MRI scans were performed prior to AAV2 delivery to anatomically determine stereotaxic coordinates for vector administration to the putamen. Animals were bilaterally infused with 1.5 × 1011 vg of
Discussion
In this study, newly developed infusion devices intended for administration of AAV2 vector in a clinical trial for Parkinson's disease were evaluated along with a comparison of infusion conditions. Mock infusions designed to test vector delivery established that essentially 100% of the intended dose could be delivered with Clinical Device B by avoidance of all contact of vector with Teflon or steel surfaces. Stereotaxic administration of AAV-hAADC-2 into the putamen of 4 non-human primates was
Acknowledgments
The authors thank the members of the Avigen manufacturing team (Jennifer Barr-Davidson, Hoc Nguyen, Joseph Prado, Shawn Chan, Hermia Kwan, James Giang, Liza Africa, Nadia Gowahari, Maria Aguago, Tannie Lee) for production of recombinant vector and Sierra (Sparks, NV) personnel for careful implementation of the in vivo portion of this study. Cheryl Pater is acknowledged for animal resource, contract management, and technical assistance. Peter Little at PAI is acknowledged for expert
References (15)
- et al.
Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach
Exp. Neurol.
(2000) - et al.
Functional effect of adeno-associated virus mediated gene transfer of aromatic l-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats
Mol. Ther.
(2001) - et al.
Striatal delivery of rAAV-hAADC to rats with preexisting immunity to AAV
Mol. Ther.
(2004) - et al.
Quantification of adeno-associated virus particles and empty capsids by optical density measurement
Mol. Ther.
(2003) - et al.
Serologic evidence for human infection with adenovirus-associated viruses
J. Natl. Cancer Inst.
(1968) - et al.
Convection-enhanced delivery of macromolecules in the brain
Proc. Natl. Acad. Sci. U. S. A.
(1994) - et al.
Novel tools for production and purification of recombinant adenoassociated virus vectors
Hum. Gene Ther.
(1998)